| Position Summary | The University of New Mexico Comprehensive Cancer Center (UNMCCC) and the Department of Internal Medicine, Division of Hematology/Oncology at the UNM School of Medicine invite physicians and physician scientists who are medical oncologists with significant experience and expertise in experimental therapeutics, preclinical and IND enabling trial design for novel targeted cancer therapies, and the design and conduct of early phase human cancer clinical trials. The successful applicant will have training, significant experience, and expertise in developing and conducting early phase clinical trials (first-in-human, phase zero, and phase I) and will be expected to lead and grow the UNMCCC Early Phase Clinical Trial Program in solid tumors, with an emphasis on rapid and informative translation from the bench-to-bedside-and-back with new therapeutics discovered and developed in concert with the UNMCCC Research Programs. This UNMCCC position includes opportunities to collaboratively support growth in drug discovery, drug repurposing, ligand-directed targeting, personalized genomics and biotechnology/nanotechnology which is a top UNMCCC priority. Superb collaborative opportunities exist with the UNMCCC Consortium partners in high-end technology and advanced material or computer sciences (at Sandia and Los Alamos National Laboratories) and GLP toxicology (Lovelace Respiratory Research Institute). This is an Open Rank, Open Track position, but experienced mid-career and senior level applicants are strongly preferred. Faculty rank and appointment will be commensurate with accomplishments. Excellent salaries, endowed positions, and start up packages are available.. The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico
and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. Its more than 120
board-certified oncology specialty physicians include cancer surgeons in every specialty (abdominal,
thoracic, bone and soft tissue, neurosurgery, genitourinary, gynecology, and head and neck cancers), adult
and pediatric hematologists/medical oncologists, gynecologic oncologists, and radiation oncologists as
well as plastic and reconstruction surgeons. They, along with more than 600 other cancer healthcare
professionals (nurses, nurse navigators, pharmacists, nutritionists, navigators, psychologists and social
workers), provide treatment to 65% of New Mexico’s cancer patients from all across the state and partner
with community health systems statewide to provide cancer care closer to home. They treated
approximately 14,000 patients in about 100,000 ambulatory clinic visits in addition to in-patient
hospitalizations at UNM Hospital. A total of nearly 400 patients participated in cancer clinical trials testing
new cancer treatments that include tests of novel cancer prevention strategies and cancer genome
sequencing. The more than 100 cancer research scientists affiliated with the UNMCCC were awarded
$35.7 million in federal and private grants and contracts for cancer research projects. Since 2015, they
have published nearly 1000 manuscripts, and promoting economic development, they filed 136 new
patents and launched 10 new biotechnology start-up companies. Finally, the physicians, scientists and
staff have provided education and training experiences to more than 500 high school, undergraduate,
graduate, and postdoctoral fellowship students in cancer research and cancer health care delivery. UNM
serves the population of New Mexico, a minority-majority state composed of nearly 50% Hispanic and 10
% American Indian. Only 62% of the state's population live in urban areas and 7% live in frontier and subfrontier
regions. UNM is deeply committed to health equity and diversity, equity and inclusion in all
aspects of training, education, workforce, scientific discovery and clinical care. Learn more at
http://cancer.unm.edu/ |
|---|
| Qualifications | Minimum Qualifications include:
1) M.D. or MD/PhD degree or equivalent with board certification in Internal Medicine;
2) Board certification in Medical Oncology and/or Hematology;
3) Significant experience and/or medical oncology fellowship or post-fellowship comprehensive training in the design and conduct of early phase clinical trials and investigator-initiated clinical trials;
4) Understanding of and/or experience in the NIH/NCI clinical trials systems including CTEP supported early phase trials, biotechnology start-up environment, FDA drug requirements and the navigating pharmaceutical industry trials and sponsorship;
5) Must be eligible to work in the U.S. Preferred Qualifications include:
1) Experience in clinical and translational research
2) Experience in clinical trial regulatory requirements and affairs;
3) A demonstrated
commitment to diversity, equity, inclusion, and student success, as well as
working with broadly diverse communities. |
|---|
|
The University of New Mexico is committed to hiring and retaining a diverse workforce. We are an Equal Opportunity Employer, making decisions without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, veteran status, disability, or any other protected class.
|